Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is a promising company in the growing field of personalized cancer therapies, as demonstrated by the strong demand for its sequencing and data analysis services. With limited competition in the MRD market and the potential for further growth in both its biopharma and clinical diagnostic businesses, we believe Personalis is positioned for success. Despite recent takeover speculation, we remain confident that Personalis will continue to thrive and maintain a strong financial position, potentially leading to further expansion in the future.

Bears say

Personalis is a young company with limited revenue sources and a high reliance on biopharma partnerships, which could significantly impact its growth if these partnerships do not materialize. The company is also facing competition from other genomic sequencing companies and may struggle to differentiate itself in the market. Additionally, there is uncertainty around its future financials, with a wide range of projections and a high risk of budget and ordering volatility from its biopharma customers.

Personalis Inc (PSNL) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Buy based on their latest research and market trends.

According to 6 analysts, Personalis Inc (PSNL) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.